STTK
NASDAQ HealthcareShattuck Labs, Inc. - Common Stock
Biotechnology
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
๐ Market Data
| Price | $7.07 |
|---|---|
| Volume | 2,104,025 |
| Market Cap | 675.24M |
| Beta | 1.060 |
| RSI (14-Day) | 63.6 |
| 200-Day MA | $4.54 |
| 50-Day MA | $5.93 |
| 52-Week High | $8.33 |
| 52-Week Low | $0.71 |
| Forward P/E | -13.71 |
| Price / Book | 5.58 |
๐ฏ Investment Strategy Scores
STTK scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (69/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (4/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find STTK in your text
Paste any article, transcript, or post โ the tool will extract STTK and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.